🇺🇸 FDA
Patent

US 9375475

Combination immunotherapy for the treatment of cancer

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9375475 (Combination immunotherapy for the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/1709, A61K39/3955